Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In patients with advanced colorectal cancer, KRAS mutation status predicts response to treatment with monoclonal antibody targeting the epithelial growth factor receptor (EGFR). Recent reports have provided evidence that KRAS mutation status has prognostic value in patients with resectable colorectal liver metastases (CLM) irrespective of treatment with chemotherapy or anti-EGFR therapy. A meta-analysis was undertaken to clarify the impact of KRAS mutation on outcomes in patients with resectable CLM.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Br J Surg

Title: The British journal of surgery

Publisher: Wiley-Blackwell

ISSN (Electronic): 1365-2168

ISSN (Print): 0007-1323

Publication date (Electronic): Sep 2015

Volume: 102

Issue: 10

Affiliations

[1 ] Departments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

[2 ] Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

[3 ] Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Article

DOI: 10.1002/bjs.9870

PubMed ID: 26206254

SO-VID: 493ff1f5-4a4b-40c9-9f63-8af2145aef1c

History

Data availability:

Comments

Comment on this article

scite_

Cited by 50

See all cited by